Get the Stockscreener App
141.88
2.29%
3.17
Illumina Inc stock is traded at $141.88, with a volume of 1.50M.
It is up +2.29% in the last 24 hours and up +10.84% over the past month.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2024 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
See More
Previous Close:
$138.71
Open:
$138
24h Volume:
1.50M
Relative Volume:
0.83
Market Cap:
$21.47B
Revenue:
$4.39B
Net Income/Loss:
$853.00M
P/E Ratio:
25.75
EPS:
5.5097
Net Cash Flow:
$556.00M
1W Performance:
+4.49%
1M Performance:
+10.84%
6M Performance:
+16.39%
1Y Performance:
+78.29%
1-Day Range:
$134.67
$142.20
1-Week Range:
$133.97
$143.01
52-Week Range:
$75.24
$155.53
Illumina Inc Stock (ILMN) Company Profile
Name
Illumina Inc
Sector
Industry
Phone
(858) 202-4500
Address
5200 ILLUMINA WAY, SAN DIEGO, CA
Compare ILMN vs TMO, DHR, IDXX, WAT, A
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ILMN
Illumina Inc
|
141.88 | 20.99B | 4.39B | 853.00M | 556.00M | 5.5097 |
TMO
Thermo Fisher Scientific Inc
|
465.00 | 172.80B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
171.16 | 121.14B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
560.11 | 44.18B | 4.45B | 1.10B | 1.06B | 13.59 |
WAT
Waters Corp
|
355.13 | 34.41B | 3.77B | 449.25M | 240.68M | 7.8556 |
A
Agilent Technologies Inc
|
115.62 | 33.53B | 7.07B | 1.29B | 993.00M | 4.5355 |
Illumina Inc Stock (ILMN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-12-25 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Jul-11-25 | Downgrade | Scotiabank | Sector Outperform → Sector Perform |
| Mar-04-25 | Reiterated | Citigroup | Neutral |
| Feb-28-25 | Downgrade | HSBC Securities | Buy → Hold |
| Feb-10-25 | Downgrade | Barclays | Equal Weight → Underweight |
| Feb-07-25 | Downgrade | TD Cowen | Buy → Hold |
| Dec-11-24 | Downgrade | Citigroup | Buy → Neutral |
| Nov-12-24 | Resumed | Morgan Stanley | Equal-Weight |
| Oct-17-24 | Upgrade | HSBC Securities | Hold → Buy |
| Aug-28-24 | Upgrade | Argus | Hold → Buy |
| Aug-16-24 | Upgrade | Daiwa Securities | Neutral → Buy |
| Aug-14-24 | Upgrade | Barclays | Underweight → Equal Weight |
| Aug-14-24 | Upgrade | TD Cowen | Hold → Buy |
| Jul-10-24 | Upgrade | Citigroup | Neutral → Buy |
| Jun-03-24 | Resumed | Jefferies | Hold |
| Jan-16-24 | Downgrade | HSBC Securities | Buy → Hold |
| Jan-04-24 | Downgrade | TD Cowen | Outperform → Market Perform |
| Dec-18-23 | Upgrade | Scotiabank | Sector Perform → Sector Outperform |
| Dec-15-23 | Upgrade | Bernstein | Underperform → Mkt Perform |
| Dec-14-23 | Initiated | Guggenheim | Buy |
| Dec-14-23 | Initiated | Stephens | Overweight |
| Dec-13-23 | Initiated | Wolfe Research | Outperform |
| Dec-12-23 | Downgrade | BofA Securities | Neutral → Underperform |
| Dec-11-23 | Upgrade | Citigroup | Sell → Neutral |
| Nov-10-23 | Downgrade | Canaccord Genuity | Buy → Hold |
| Sep-28-23 | Initiated | Bernstein | Underperform |
| Jul-05-23 | Resumed | JP Morgan | Neutral |
| Jan-25-23 | Downgrade | Argus | Buy → Hold |
| Jan-05-23 | Initiated | Scotiabank | Sector Perform |
| Dec-12-22 | Downgrade | Citigroup | Neutral → Sell |
| Dec-07-22 | Initiated | RBC Capital Mkts | Outperform |
| Oct-04-22 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Sep-28-22 | Upgrade | Evercore ISI | In-line → Outperform |
| Aug-25-22 | Initiated | Credit Suisse | Neutral |
| Jul-13-22 | Downgrade | Barclays | Equal Weight → Underweight |
| Jan-18-22 | Upgrade | Stifel | Hold → Buy |
| Jan-11-22 | Upgrade | Barclays | Underweight → Equal Weight |
| Jan-07-22 | Upgrade | BofA Securities | Underperform → Neutral |
| Jan-06-22 | Resumed | Morgan Stanley | Equal-Weight |
| Jan-06-22 | Resumed | Piper Sandler | Overweight |
| Oct-15-21 | Resumed | Cowen | Outperform |
| Aug-19-21 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Jun-01-21 | Upgrade | Evercore ISI | Underperform → In-line |
| Mar-31-21 | Downgrade | Atlantic Equities | Overweight → Neutral |
| Mar-31-21 | Upgrade | Canaccord Genuity | Hold → Buy |
| Mar-03-21 | Initiated | Barclays | Underweight |
| Dec-22-20 | Upgrade | Piper Sandler | Neutral → Overweight |
| Dec-17-20 | Upgrade | BTIG Research | Neutral → Buy |
| Oct-13-20 | Downgrade | Guggenheim | Buy → Neutral |
| Sep-30-20 | Initiated | Atlantic Equities | Overweight |
| Sep-29-20 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Sep-22-20 | Downgrade | Stifel | Buy → Hold |
| Sep-22-20 | Downgrade | UBS | Buy → Neutral |
| Sep-21-20 | Upgrade | Guggenheim | Neutral → Buy |
| Sep-21-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Sep-09-20 | Initiated | Morgan Stanley | Equal-Weight |
| Aug-07-20 | Downgrade | Evercore ISI | In-line → Underperform |
| Aug-07-20 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jul-07-20 | Downgrade | Guggenheim | Buy → Neutral |
| Apr-24-20 | Downgrade | Citigroup | Buy → Neutral |
| Apr-21-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jan-08-20 | Initiated | Wells Fargo | Underweight |
| Jan-07-20 | Initiated | Citigroup | Buy |
| Jan-02-20 | Downgrade | Evercore ISI | Outperform → In-line |
| Nov-15-19 | Initiated | Stifel | Buy |
| Oct-25-19 | Initiated | Guggenheim | Buy |
View All
Illumina Inc Stock (ILMN) Latest News
Dna Forensic Market Is Booming So Rapidly | Agilent Technologies, Illumina, Bio-Rad Laboratories - openPR.com
Illumina Inc. Stock (US4523271090): Analyst Ratings and Price Targets in Focus - AD HOC NEWS
Illumina SVP Jakob Wedel Christensen sells $97,328 in stock - Investing.com
Illumina (NASDAQ: ILMN) SVP logs 700-share sale and 233-share tax withholding - Stock Titan
Illumina Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Illumina Patent Lawsuit Targets BillionToOne Prenatal Tests (1) - Bloomberg Law News
Illumina showcases multi-omics potential to advance precision medicine in India - Indian Pharma Post
Next-Generation Genome Mapping Market is Thriving Worldwide | - openPR.com
Microfluidics Market Competitive Analysis to 2031 | Illumina, Inc, microfluidic ChipShop GmbH, Danaher etc. - openPR.com
Illumina Inc. stock outperforms competitors on strong trading day - MarketWatch
[144] ILLUMINA, INC. SEC Filing - Stock Titan
Global DNA Microarray Market is Predicted to Exhibit Remarkable Growth at a CAGR of ~7% by 2034 | DelveInsight - GlobeNewswire Inc.
Uber, Exxon Mobil, Illumina, Diamondback Energy: CNBC's 'Final Trades' - Dailyhunt
ILMN Stock Price, Quote & Chart | ILLUMINA INC (NASDAQ:ILMN) - ChartMill
Whole Exome Sequencing Market key players 2024-2031: Illumina, Inc., Centogene AG, Eurofins Scientific etc - openPR.com
Assessing Illumina (ILMN) Valuation After Earnings Beat Guidance Hike And Expanded Buyback - Yahoo Finance
Illumina Shareholder Alert - TMX Newsfile
Here's Why Illumina (ILMN) is a Strong Growth Stock - Yahoo Finance
Epigenetics Market is expected to Hit US$ 7.10 Billion by 2033 | - openPR.com
Illumina, Inc. Q1 2026 Financial Report: Earnings, Revenue, Risk Factors & Forward-Looking Statements 18 24 37 - Minichart
Final Trades: Uber, Exxon, Illumina and Diamondback Energy - CNBC
Illumina Partners with Florida State University Lab for Rare Disease Genome Sequencing - Clinical Lab Products
Genomics Market size is anticipated to reach US$ 83.61 billion - openPR.com
Illumina, Inc. (ILMN) Stock Analysis: Exploring Its 33.82% Return On Equity - DirectorsTalk Interviews
Illumina (ILMN) Q1 2026 Earnings: Revenue Beat and Raised GuidanceNews and Statistics - IndexBox
Illumina, Inc. 2026 Q1ResultsEarnings Call Presentation (NASDAQ:ILMN) 2026-05-03 - Seeking Alpha
ILMN Q1 Deep Dive: Clinical Sequencing Fuels Growth as NovaSeq X Demand Surges - Yahoo Finance
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Illumina (ILMN), Moderna (MRNA) and Dexcom (DXCM) - The Globe and Mail
Illumina revenue up 4.8% to USD 1.09B in Q1 2026 - Medical Buyer
Jennison Associates LLC Has $26.21 Million Stock Position in Illumina, Inc. $ILMN - MarketBeat
MSN Money - MSN
[10-Q] ILLUMINA, INC. Quarterly Earnings Report - Stock Titan
Illumina jumps 7.1% as Q1 results top expectations and full-year outlook rises - Quiver Quantitative
Illumina (NASDAQ:ILMN) Stock Price Expected to Rise, JPMorgan Chase & Co. Analyst Says - MarketBeat
Here’s Why Illumina Stock Could Deliver 8% Annual Returns Through 2028 - TIKR.com
ILMN Stock Up on Q1 Earnings & Revenue Beat, Margins Expand, '26 View Up - Yahoo Finance
Canaccord cuts Illumina stock price target on competition concerns - Investing.com UK
Illumina, Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
Illumina, Inc. (NASDAQ:ILMN) Q1 2026 Earnings Call Transcript - Insider Monkey
Canaccord cuts Illumina stock price target on competition concerns By Investing.com - Investing.com Canada
Illumina Q1 2026 earnings preview - MSN
Evercore ISI raises Illumina stock price target on strong results By Investing.com - Investing.com Canada
Evercore ISI raises Illumina stock price target on strong results - Investing.com
Florida Hospital Association adds Gaye Walker as communications VP - Florida Politics
ILMN SEC FilingsIllumina Inc 10-K, 10-Q, 8-K Forms - Stock Titan
ILMN Fundamental Analysis & Valuation | Fair Value & Financial Strength | ILLUMINA INC (NASDAQ:ILMN) - ChartMill
Earnings Call Summary | Illumina(ILMN.US) Q1 2026 Earnings Conference - Moomoo
Illumina Q1 2026 slides: earnings beat on clinical strength, margins expand - Investing.com Canada
Illumina (NASDAQ:ILMN) Releases Earnings Results, Beats Estimates By $0.10 EPS - MarketBeat
Illumina (ILMN) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates - Yahoo News Malaysia
Illumina set to report earnings amid rising Roche competition - Investing.com
Illumina Inc Stock (ILMN) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.52%
0.04%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):